Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity
- ASC30 subcutaneous (SQ) depot formulation achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of 7.5% at week 16 after three monthly doses. - ASC30 SQ depot formulation maintained weight loss for the four...
Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase II Results
HONG KONG, March 5, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the latest long-term survival analysis data from the China pivotal registrational Phase II study (COMPASSION-03/AK104-201) of cadonilimab as a...
Emily Bao Unveils 2026 Strategic Roadmap at Solana Accelerate APAC: 24/7 Perpetual Trading Is Coming to the DEX
DUBAI, UAE, Feb. 13, 2026 /PRNewswire/ -- As Consensus 2026 brings together leaders and changemakers in digital asset innovation, Byreal co-founder Emily Bao today unveiled the protocol's ambitious 2026 strategic roadmap at Solana Accelerate APAC,...
Dr. Sultan Al Jaber Unveils 'World First' 24/7 Renewables Project; Global Megatrends Call for New Path to Socioeconomic Progress
At opening of ADSW 2025, HE Dr. Al Jaber unveils world's first renewable and battery storage facility to provide uninterrupted power, at scale, around the clock in Abu Dhabi. Unwavering support of UAE leadership enables breakthrough to "moonshot...
